

SPARC/Sec/SE/2019-20/054

11th February 2020

To **National Stock Exchange of India Ltd.** Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

BSE Limited P J Towers, Dalal street, Mumbai - 400001

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Update on TACLANTIS[™] (Paclitaxel Injection Concentrate for Suspension) NDA

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the New Drug Application (NDA) for Taclantis[™] (Paclitaxel Injection Concentrate for Suspension).

Company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised.

We request you to kindly take the same on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Limited



For Debashis Dey Company Secretary



Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India. Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life